# Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

> **NCT04963283** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 48 (actual)

## Conditions studied

- Colorectal Adenocarcinoma
- Colon Cancer
- Colon Adenocarcinoma
- Rectum Cancer
- Rectal Cancer
- Rectal Adenocarcinoma
- Colorectal Cancer

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04963283
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-23
- **Primary completion:** 2026-02-24
- **Final completion:** 2027-02-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04963283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04963283, "Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04963283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*